Skip to search formSkip to main contentSkip to account menu

acipimox

Known as: 5-methylpyrazine-2-carboxylic acid 4-oxide, 5-methylpyrazinecarboxylic acid 4-oxide 
A niacin derivative and nicotinic acid analog with activity as a hypolipidemic agent. Acipimox has special application for the treatment of… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Hypolipidemic AgentsPyrazines

Narrower (2)

NediosOlbetam

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Alteraciones neuroendocrinas en la obesidad
Se han descrito numerosas alteraciones endocrinológicas en la obesidad.  Tanto la secreción espontánea de hormona de crecimiento… 
2006
2006
[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].
AIM: Assessment of effects of a 3-month course of atorvastatin and a nicotinic acid derivative acipimox on the lipid spectrum… 
2006
2006
[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].
AIM Assessment of effects of a 3-month course of atorvastatin and a nicotinic acid derivative acipimox on the lipid spectrum… 
2004
2004
FFAs are not involved in regulation of gluconeogenesis and glycogenolysis in adults with uncomplicated P. falciparum malaria.
In normal subjects, elevation of plasma free fatty acid (FFA) levels stimulates gluconeogenesis (GNG) and inhibits glycogenolysis… 
2002
2002
Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: Comparison of image quality with hyperinsulinemic euglycemic clamping in…
BackgroundImage quality of cardiac fluorine-18-deoxyglucose (FDG) studies is highly dependent on the metabolic conditions during… 
1995
1995
Effects of Acipimox on the metabolism of free fatty acids and very low lipoprotein triglyceride.
The mechanism of triglyceride lowering by Acipimox, a nicotine acid analogue, was examined in a group of five moderately… 
1989
1989
Effect of acipimox on plasma glucose levels in patients with non-insulin-dependent diabetes mellitus
This study was carried out in order to verify whether an antilipolytic drug, acipimox, wich may significantly reduce FFA levels… 
1987
1987
Long-term multicentre trial with acipimox in diabetic patients with hyperlipoproteinemia
Acipimox is a new lipid-lowering agent with long-lasting antilipolytic activity chemically related to nicotinic acid (1,2). The… 
1985
1985
A pilot study of the pharmacokinetics and triglyceride lowering activity of acipimox in dialyzed uremic patients.
The pharmacokinetics of acipimox was studied in 6 dialyzed uremic patients given single oral doses of 50 mg. Acipimox was not… 
1982
1982
[Acipimox treatment of hyperlipidemia type II].
The hypolipidemic effect of acipimox, a new inhibitor of lipolysis, was investigated in a double blind crossover trial versus…